Physician profile
Peter B Hardin
NPI 1366419814
$2,644.64
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $222 · 2021: $203 · 2022: $547 · 2023: $798 · 2024: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $976.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $247.64 | 2019-2023 | Darzalex, Erleada, Imbruvica |
| Merck Sharp & Dohme LLC | $238.82 | 2019-2023 | Keytruda, Lynparza |
| Amgen INC. | $200.62 | 2019-2023 | Lumakras |
| Incyte Corporation | $189.15 | 2021-2024 | Monjuvi, Jakafi, Pemazyre |
| Seagen INC. | $150.13 | 2022-2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $135.34 | 2019-2024 | Enhertu |
| Genzyme Corporation | $134.88 | 2019-2021 | |
| Celgene Corporation | $84.56 | 2019-2020 | |
| Lilly USA, LLC | $84.02 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $76.86 | 2022 | |
| Genentech USA, INC. | $60.10 | 2022-2024 | Tecentriq |
| Rigel Pharmaceuticals, INC. | $59.08 | 2022-2023 | Tavalisse, Rezlidhia |
| Puma Biotechnology, INC. | $57.92 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.67 | 2019-2023 | |
| Tesaro, INC. | $53.07 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hardin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.